litlas
Log inCreate account

Stephen K. Tyring

Active 1992–2025

148
Papers
24,673
Citations
90
h-index
143
i10-index

Citations

Citations per year for Stephen K. Tyring1986: 1 citations1990: 1 citations1993: 7 citations1994: 6 citations1995: 10 citations1996: 34 citations1997: 40 citations1998: 27 citations1999: 47 citations2000: 54 citations2001: 62 citations2002: 94 citations2003: 85 citations2004: 101 citations2005: 115 citations2006: 125 citations2007: 162 citations2008: 160 citations2009: 137 citations2010: 141 citations2011: 152 citations2012: 152 citations2013: 153 citations2014: 140 citations2015: 160 citations2016: 204 citations2017: 243 citations2018: 258 citations2019: 735 citations2020: 701 citations2021: 648 citations2022: 450 citations2023: 402 citations2024: 563 citations2025: 301 citations2026: 2 citations1987–1989: no citations, so these years are not shown1991–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,318 citing papers, 28.2% of this breakdownUnited Kingdom: 611 citing papers, 7.4% of this breakdownGermany: 592 citing papers, 7.2% of this breakdownCanada: 459 citing papers, 5.6% of this breakdownChina: 409 citing papers, 5% of this breakdownItaly: 404 citing papers, 4.9% of this breakdownFrance: 307 citing papers, 3.7% of this breakdownSwitzerland: 249 citing papers, 3% of this breakdownSpain: 246 citing papers, 3% of this breakdownJapan: 208 citing papers, 2.5% of this breakdownAustralia: 202 citing papers, 2.5% of this breakdownNetherlands: 195 citing papers, 2.4% of this breakdown
0%28.2%Other 24.6%

Institutions

Fields

  • Medicine52%
  • Immunology and Microbiology32.2%
  • Biochemistry, Genetics and Molecular Biology7.4%
  • Neuroscience5.6%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Psychology0.4%
  • Other1.9%

Topics

  • Psoriasis: Treatment and Pathogenesis10.8%
  • Dermatology and Skin Diseases6.9%
  • Spondyloarthritis Studies and Treatments4.9%
  • Herpesvirus Infections and Treatments4.4%
  • Cytomegalovirus and herpesvirus research2.7%
  • Cervical Cancer and HPV Research2.2%
  • Other68.1%

Coauthors

All papers

Open in search
  1. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

    Authors: Richard G. Langley, Boni E. Elewski, Mark Lebwohl, Kristian Reich, C.E.M. Griffiths, Kim Papp, L. Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson, Enrique Rivas, Tsen‐Fang Tsai, Norman Wasel, Stephen K. Tyring, Thomas Salko, Isabelle Hampele, Marianne Notter, Alexander Karpov, Silvia Helou, C. Papavassilis - New England Journal of Medicine 2014 cited by 1,964

  2. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

    Authors: Kristian Reich, Kim Papp, Andrew Blauvelt, Stephen K. Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, N. Cichanowitz, Qing Li, Kenneth Liu, Carmen La Rosa, Stuart Green, Alexa B. Kimball - The Lancet 2017 cited by 556

  3. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

    Authors: Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth B. Gordon, Jolanta Węgłowska, L. Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco A. Kerdel, April W. Armstrong, Georg Stingl, Alexa B. Kimball, H. Bachelez, Jashin J. Wu, Jeffrey Crowley, Richard G. Langley, Tomasz Blicharski, C. Paul, J.‐P. Lacour, Stephen K. Tyring, Leon Kircik, Sergio Chimenti, Kristina Callis Duffin, Jerry Bagel, John Koo, Gary Aras, Joanne Li, Wenjie Song, Cassandra E. Milmont, Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian L. Kotzin, Ajay Nirula - New England Journal of Medicine 2015 cited by 806

  4. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

    Authors: Kim Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G. Krueger, J.‐P. Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen K. Tyring, B Berner, Sudha Visvanathan, Chandrasena Pamulapati, Nathan Bennett, Mary Flack, Paul Scholl, Steven J. Padula - New England Journal of Medicine 2017 cited by 511

  5. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial

    Authors: Stephen K. Tyring, Alice B. Gottlieb, Kim Papp, Ken Gordon, Craig L. Leonardi, Andrea Wang, Deepa Lalla, Michael Woolley, Angelika Jahreis, Ralph Zitnik, David Cella, Ranga Krishnan - The Lancet 2005 cited by 1,069

  6. Recommendations for the Management of Herpes Zoster

    Authors: Robert H. Dworkin, Robert W. Johnson, Judith Breuer, John W. Gnann, Myron J. Levin, Miroslav Bačkonja, Robert F. Betts, Anne A. Gershon, Maija Haanpää, Michael W. McKendrick, Turo Nurmikko, Anne Louise Oaklander, Michael N. Oxman, Deborah Pavan Langston, Karin L. Petersen, Michael C. Rowbotham, Kenneth E. Schmader, Brett R. Stacey, Stephen K. Tyring, Albert J. M. van Wijck, Mark S. Wallace, Sawko W. Wassilew, Richard J. Whitley - Clinical Infectious Diseases 2006 cited by 845

  7. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial

    Authors: Bruce Strober, Linda Stein Gold, Robert Bissonnette, April W. Armstrong, Leon Kircik, Stephen K. Tyring, Stephen C. Piscitelli, Philip M. Brown, David S. Rubenstein, Anna M. Tallman, Mark Lebwohl - Journal of the American Academy of Dermatology 2022 cited by 88

  8. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

    Authors: Andrew Blauvelt, Kim Papp, Alice B. Gottlieb, Abel Jarell, Kristian Reich, Catherine Maari, Kenneth B. Gordon, Laura K. Ferris, Richard G. Langley, Yayoi Tada, Renata Gontijo Lima, Hany Elmaraghy, Gaia Gallo, L. Renda, S‐M. Park, Russel Burge, Jerry Bagel, the IXORA‐R Study Group, Ronald Vender, Mark Lomaga, Isabelle Delorme, Chih-ho Hong, Richard L. Langley, Lorne Albrecht, Lyn Guenther, Catherine Maari, Kim Papp, Kamal Ohson, Kirk Barber, Charles Lynde, Aditya Gupta, Leslie Rosoph, Jean‐Sébastien Gauthier, Melinda Gooderham, Norman Wasel, Mani Raman, Marni Wiseman, David Greenstein, Abel Jarell, C. A. L. Moon, Lani Clark, S. Jazayeri, Michael Bukhalo, Angela Moore, Tiffani K. Hamilton, Aron Gewirtzman, Lydie Hazan, Jeffrey Crowley, Craig Teller, Matthew Zirwas, Stacy Smith, Mark Lee, Stephen K. Tyring, Patricia Lee, Sunil Dhawan, Craig L. Leonardi, Amarilis Perez‐De Jesus, Wendy McFalda, Ellen Frankel, Paul S. Yamauchi, Scott Fretzin, Rocco Serrao, Todd Schlesinger, Scott Gottlieb, Peter Jenkin, Rola Gharib, Steven A. Davis, Navid Nami, Zoe Diana Draelos, Lloyd Godwin, Cindy E. Owen, Megan N. Landis, William Abramovits, Samuel Sanchez‐Rivera, Abby Van Voorhees, David Fivenson, Francisco A. Kerdel, Seth Forman, Jeffrey S. Weinberg, José González-Chávez, Brent Boyce, Linda Stein‐Gold, Charles P. Hudson, Constance Brown, James Coggi, Christina Feser, Rion Forconi, Sandra Johnson, Mark McCune, Lawrence Green, Vandana Madkan, Dana Maxwell Shipp, Kenneth B. Gordon, Jill Waibel, Oscar Soto‐Raices, Jennifer Cather, Scott Miller, John P. Scott, Douglas Young, Jessica Kaffenberger and 42 more - British Journal of Dermatology 2019 cited by 172

  9. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

    Authors: Howard Sofen, Robert Bissonnette, Gil Yosipovitch, Jonathan I. Silverberg, Stephen K. Tyring, Wei Jing Loo, Matthew Zook, Mark Lee, Liangxing Zou, Guang-Liang Jiang, John F. Paolini - EClinicalMedicine 2023 cited by 99

  10. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis

    Authors: Andrew Blauvelt, Steven Kempers, Edward Lain, Todd Schlesinger, Stephen K. Tyring, Seth Forman, Glynis Ablon, George M. Martin, Hui Wang, David L. Cutler, Jane Fang, Min-Fun Rudolf Kwan - New England Journal of Medicine 2021 cited by 161

  11. Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers

    Authors: Nehal N. Mehta, Daniel B. Shin, Aditya A. Joshi, Amit K. Dey, April W. Armstrong, Kristina Callis Duffin, Zelma C. Chiesa Fuxench, Charlotte Harrington, Rebecca A. Hubbard, Robert E. Kalb, Alan Menter, Daniel J. Rader, Muredach P. Reilly, Eric L. Simpson, Junko Takeshita, Drew A. Torigian, Thomas Werner, Andrea B. Troxel, Stephen K. Tyring, Suzette Báez Vanderbeek, Abby S. Van Voorhees, Martin P. Playford, Mark A. Ahlman, Abass Alavi, Joel M. Gelfand - Circulation Cardiovascular Imaging 2018 cited by 147

  12. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

    Authors: Alan Menter, Stephen K. Tyring, Kenneth B. Gordon, Alexa B. Kimball, Craig L. Leonardi, Richard G. Langley, Bruce Strober, Martin Kaul, Yihua Gu, Martin M. Okun, Kim Papp - Journal of the American Academy of Dermatology 2007 cited by 883

  13. Viral Oncology: Molecular Biology and Pathogenesis

    Authors: Uyen Ngoc Mui, Christopher T. Haley, Stephen K. Tyring - Journal of Clinical Medicine 2017 cited by 221

  14. Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis

    Authors: Joel M. Gelfand, Daniel B. Shin, April W. Armstrong, Stephen K. Tyring, Andrew Blauvelt, Scott Gottlieb, Benjamin Lockshin, Robert E. Kalb, Robert Fitzsimmons, Justin Rodante, Philip M. Parel, Grigory A. Manyak, Laurel Mendelsohn, Megan H. Noe, Maryte Papadopoulos, Maha N. Syed, Thomas Werner, Joy Wan, Martin P. Playford, Abass Alavi, Nehal N. Mehta - JAMA Dermatology 2022 cited by 44

  15. Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis

    Authors: Andrew Blauvelt, Eric L. Simpson, Stephen K. Tyring, Lisa A. Purcell, Brad Shumel, Christopher D. Petro, Bolanle Akinlade, Abhijit Gadkari, Laurent Eckert, Neil M.H. Graham, Gianluca Pirozzi, Robert R. Evans - Journal of the American Academy of Dermatology 2018 cited by 137

  16. A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)

    Authors: Joel M. Gelfand, Daniel B. Shin, Kristina Callis Duffin, April Armstrong, Andrew Blauvelt, Stephen K. Tyring, Alan Menter, Scott Gottlieb, Benjamin Lockshin, Eric L. Simpson, Farid Kianifard, R. Sarkar, Elisa Muscianisi, Jennifer Steadman, Mark A. Ahlman, Martin P. Playford, Aditya A. Joshi, Amit K. Dey, Thomas Werner, Abass Alavi, Nehal N. Mehta - Journal of Investigative Dermatology 2020 cited by 95

  17. Hand-foot-and-mouth disease caused by coxsackievirus A6 on the rise.

    Authors: Brooks David Kimmis, Christopher Downing, Stephen K. Tyring - 2018 cited by 109

  18. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

    Authors: Kim Papp, Stephen K. Tyring, M. Lahfa, Jörg C. Prinz, C.E.M. Griffiths, Arline Nakanishi, Ralph Zitnik, P.C.M. van de Kerkhof, the Etanercept Psoriasis Study Group - British Journal of Dermatology 2005 cited by 692

  19. Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes

    Authors: Lawrence Corey, Anna Wald, Raj Patel, Stephen L. Sacks, Stephen K. Tyring, Terri Warren, John M. Douglas, Jorma Paavonen, Rhoda Ashley Morrow, Karl R. Beutner, Leonid S. Stratchounsky, Grégory Mertz, Oliver N. Keene, Helen Watson, Dereck Tait, Mauricio Vargas‐Cortes - New England Journal of Medicine 2003 cited by 727

  20. Hailey–Hailey disease treated with dupilumab: a case series

    Authors: Nujood Alzahrani, J. Grossman‐Kranseler, Ritu Swali, Kristin Fiumara, Pedro Zancanaro, Stephen K. Tyring, David Rosmarin - British Journal of Dermatology 2021 cited by 55

  21. Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis

    Authors: Stephen K. Tyring, Kenneth B. Gordon, Yves Poulin, Richard G. Langley, Alice B. Gottlieb, M. Dunn, Angelika Jahreis - Archives of Dermatology 2007 cited by 321

  22. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

    Authors: Andrew Blauvelt, Kristian Reich, Tsen‐Fang Tsai, Stephen K. Tyring, F. Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Ronald Vender, Sophie Hugot, R. You, M. Milutinovic, Diamant Thaçi - Journal of the American Academy of Dermatology 2016 cited by 304

  23. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

    Authors: Kim Papp, James G. Krueger, Steven R. Feldman, Richard G. Langley, Diamant Thaçi, Hideshi Torii, Stephen K. Tyring, Robert Wołk, Annie Gardner, Charles A. Mebus, Huaming Tan, Yingchun Luo, Pankaj Gupta, Lotus Mallbris, Svitlana Tatulych - Journal of the American Academy of Dermatology 2016 cited by 155

  24. The oral Janus kinase/spleen tyrosine kinase inhibitorASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

    Authors: Robert Bissonnette, Catherine Maari, Seth Forman, Neal Bhatia, M. Lee, Joseph F. Fowler, Stephen K. Tyring, David M. Pariser, Howard Sofen, Sunil Dhawan, M. Zook, David J. Zammit, Helen Usansky, L. Denis, Niranjan Rao, Teresa Song, Ana B. Pavel, Emma Guttman‐Yassky - British Journal of Dermatology 2019 cited by 129